Q2 FY2026 EarningsQ2 FY26 results slightly beat consensus across key profitability metrics: revenue was $1.15M vs. $1.11M expected, and GAAP EPS was -$0.24 vs. -$0.26 expected. Net loss of $42.1M was narrower than the $46.3M consensus due to successful cost-reduction initiatives following the May 2025 workforce reduction. Strategic progress remains the primary driver, with PM577a clearing IND/CTA for a global Phase 1/2 study and PM359 securing RMAT designation, while cash runway is confirmed into 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Prime Medicine(PRME) the Revenue is 1.154 M (+3.5%), Beat estimate;the EBIT is -43.29 M (+18.91%), Beat estimate;the EPS is -0.24 (+41.46%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B3.50%
0.00B0.89%
+0.00B4.39%
EBITExceed expectations
-0.04B18.91%
-0.05B9.86%
+0.00B9.05%
EPSExceed expectations
-0.2441.46%
-0.256237.51%
+0.01623.95%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf